Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 137,292
  • Shares Outstanding, K 55,584
  • Annual Sales, $ 25,730 K
  • Annual Income, $ -106,140 K
  • 60-Month Beta 3.12
  • Price/Sales 7.80
  • Price/Cash Flow N/A
  • Price/Book 1.82
Trade CLLS with:

Options Overview Details

View History
  • Implied Volatility 135.80% ( +135.80%)
  • Historical Volatility 50.06%
  • IV Percentile 82%
  • IV Rank 54.50%
  • IV High 244.92% on 11/16/23
  • IV Low 5.12% on 03/12/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 905
  • Open Int (30-Day) 872

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +172,341.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +9.13%
on 04/18/24
2.95 -14.91%
on 04/03/24
+0.10 (+4.15%)
since 03/19/24
3-Month
2.30 +9.13%
on 04/18/24
3.13 -19.81%
on 02/08/24
-0.18 (-6.69%)
since 01/19/24
52-Week
0.96 +160.71%
on 10/26/23
3.77 -33.48%
on 12/20/23
+0.48 (+23.65%)
since 04/19/23

Most Recent Stories

More News
There's a Lot of Upside For Emerging Gene-Editing Companies

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

CRBU : 3.89 (-0.51%)
CLLS : 2.52 (+2.02%)
DTIL : 10.10 (-5.78%)
SGMO : 0.5267 (+8.58%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 484.32 (-3.48%)
AAPL : 165.15 (-1.13%)
SESN : 12.5760 (+7.29%)
HOTH : 1.2000 (+1.69%)
CLLS : 2.52 (+2.02%)
ORIC : 8.99 (-5.47%)
PFE : 25.76 (+1.46%)
TGTX : 13.73 (-1.86%)
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil

Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

BMY : 48.61 (+0.64%)
MRK : 125.60 (+0.30%)
CLLS : 2.52 (+2.02%)
IOVA : 11.31 (-3.50%)
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.

ACAD : 16.85 (-1.29%)
CLLS : 2.52 (+2.02%)
IOVA : 11.31 (-3.50%)
ARDS : 0.0600 (-2.44%)
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy

Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.

BMY : 48.61 (+0.64%)
MRK : 125.60 (+0.30%)
CLLS : 2.52 (+2.02%)
IOVA : 11.31 (-3.50%)
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using...

CLLS : 2.52 (+2.02%)
HGEN : 0.0002 (-84.62%)
OMGA : 2.41 (-0.41%)
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

BMY : 48.61 (+0.64%)
MRK : 125.60 (+0.30%)
CLLS : 2.52 (+2.02%)
IOVA : 11.31 (-3.50%)
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

  IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR...

CLLS : 2.52 (+2.02%)
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully...

CLLS : 2.52 (+2.02%)
Cellectis to Report Second Quarter 2022 Financial Results

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its...

CLLS : 2.52 (+2.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 2.96
2nd Resistance Point 2.80
1st Resistance Point 2.63
Last Price 2.52
1st Support Level 2.30
2nd Support Level 2.14
3rd Support Level 1.97

See More

52-Week High 3.77
Fibonacci 61.8% 2.70
Last Price 2.52
Fibonacci 50% 2.37
Fibonacci 38.2% 2.04
52-Week Low 0.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar